Cargando…
Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants
Autores principales: | Vanhove, Bernard, Marot, Stéphane, So, Ray T., Gaborit, Benjamin, Evanno, Gwénaëlle, Malet, Isabelle, Lafrogne, Guillaume, Mevel, Edwige, Ciron, Carine, Royer, Pierre-Joseph, Lheriteau, Elsa, Raffi, François, Bruzzone, Roberto, Mok, Chris Ka Pun, Duvaux, Odile, Marcelin, Anne-Geneviève, Calvez, Vincent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176966/ https://www.ncbi.nlm.nih.gov/pubmed/37187748 http://dx.doi.org/10.3389/fimmu.2023.1208705 |
Ejemplares similares
-
XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants
por: Vanhove, Bernard, et al.
Publicado: (2021) -
LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation
por: Rousse, Juliette, et al.
Publicado: (2023) -
Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study
por: Gaborit, Benjamin, et al.
Publicado: (2021) -
Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial
por: Gaborit, Benjamin, et al.
Publicado: (2023) -
Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial
por: Gaborit, Benjamin, et al.
Publicado: (2021)